Mersana Therapeutics Inc. (NASDAQ:MRSN) – Research analysts at Wedbush upped their Q2 2018 EPS estimates for shares of Mersana Therapeutics in a report issued on Tuesday, May 15th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.58) per share for the quarter, up from their previous estimate of ($0.76). Wedbush also issued estimates for Mersana Therapeutics’ Q3 2018 earnings at ($0.62) EPS, Q4 2018 earnings at ($0.66) EPS, FY2018 earnings at ($2.41) EPS, FY2019 earnings at ($2.27) EPS, FY2020 earnings at ($2.38) EPS, FY2021 earnings at ($2.29) EPS and FY2022 earnings at ($1.44) EPS.
Other equities analysts have also recently issued reports about the company. HC Wainwright set a $33.00 target price on Mersana Therapeutics and gave the stock a “buy” rating in a report on Monday, March 19th. Zacks Investment Research raised Mersana Therapeutics from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Thursday, March 22nd. Cowen reissued a “buy” rating on shares of Mersana Therapeutics in a report on Monday, April 16th. Finally, ValuEngine raised Mersana Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $25.67.
Mersana Therapeutics (NASDAQ:MRSN) last issued its earnings results on Monday, May 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.07. Mersana Therapeutics had a negative return on equity of 157.55% and a negative net margin of 263.80%. The business had revenue of $3.06 million during the quarter, compared to analysts’ expectations of $3.49 million.
A number of hedge funds have recently added to or reduced their stakes in MRSN. Bank of New York Mellon Corp acquired a new stake in Mersana Therapeutics during the 3rd quarter valued at $231,000. California State Teachers Retirement System acquired a new stake in Mersana Therapeutics during the 3rd quarter valued at $142,000. Victory Capital Management Inc. increased its holdings in Mersana Therapeutics by 11.0% during the 4th quarter. Victory Capital Management Inc. now owns 57,930 shares of the company’s stock valued at $952,000 after purchasing an additional 5,730 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in Mersana Therapeutics during the 4th quarter valued at $197,000. Finally, BlackRock Inc. increased its holdings in Mersana Therapeutics by 118.9% during the 4th quarter. BlackRock Inc. now owns 577,299 shares of the company’s stock valued at $9,485,000 after purchasing an additional 313,516 shares in the last quarter. 75.64% of the stock is owned by hedge funds and other institutional investors.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.